NEW YORK (GenomeWeb News) – Advanced Biological Laboratories said today it signed a non-exclusive agreement with Roche Diagnostics for the promotion of certain ABL products.
In particular, the deal is aimed at promoting ABL's next-generation sequencing platform called DeepChek with Roche's NGS systems, the 454 GS Junior and 454 GS FLX+, for molecular virology. The deal covers Europe, the Middle East, Africa, and Latin America.
DeepChek is a solution for managing and analyzing NGS data.
The principal goals of the deal are to "provide our mutual customers with integrated sequencing and analysis systems delivering the required quality, sensitivity, and meaningful genotyping, and drug resistance reporting for personalized healthcare," ABL said.
Financial and other terms were not disclosed.
ABL is a Luxembourg-based developer of informatics tools for personalized medicine. In June it acquired all the assets of Evivar Medical.